Grace Halsey

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.

Levels of acetyl-L-carnitine and free carnitine correlated significantly with disease severity, particularly in women with moderate and severe Alzheimer dementia.

Only 25% of people who self-monitor health use the data to inform their physicians.

The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.

Hesitancy about vaccination against dangerous communicable diseases remains a public health problem, particularly when the hesitant are living with immunocompromising conditions.

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

The new research augments data on efficacy of RSVPreF in older, high-risk adults that was not captured in phase 3 pivotal clinical trials, authors said.

Agency review determined the pouches to be less harmful to health than cigarettes and an aid to smoking cessation but did not declare the products "safe."

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Peter McAllister, MD,

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.

Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

Migraine expert Peter McAllister, MD, a long-time principal investigator for migraine studies, wonders if study design in this area needs to be re-evaluated.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.